The Latest Breaking News from BMY

While Bristol-Myers Squibb has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Bristol Myers Squibb Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions.

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.

Although Bristol-Myers Squibb has outshined relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Bristol-Myers has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Bristol-Myers Squibb is poised to announce its first-quarter results this month, and analysts predict a triple-digit growth in the company’s bottom-line figure.

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine industry is expected to witness significant growth and expansion. Hence, it could be wise to invest in quality precision medicine stocks Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) that are transforming…